Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics ("Argos" or "the Company") has closed its initial public offering. The initial public offering price was $8.00 per ordinary share. Argos' ordinary shares have listed on the NASDAQ Global Market and began trading under the symbol "ARGS" on 7 February 2014.